Fatostatin |
Inhibition of ER-Golgi translocation of SCAP/SREBPs |
GBM |
U87-MG (−) |
U87-MG (5, 30 mg/kg) |
[108] |
Prostate |
LNCap(10.4), C4–2B(9.1), PC3 (15.8), DU145 (9.5) |
C4–2B, PC3,DU145(15 mg/kg) |
[109, 111] |
Lung |
A549 (−), PC9 (−) |
None |
[141] |
Pancreatic |
MIA PaCa-2 (14.5) |
None |
[72] |
Betulin |
Inhibition of ER-Golgi translocation of SREBPs |
Prostate |
LNCaP (−), PC3 (−) |
None |
[142] |
Breast |
MCF7 (−) |
MCF7 (50,100 mg/kg) |
[143] |
Lung |
A549 (−), PC9 (−) |
A549 (20 mg/kg) |
[141] |
HCC |
None |
Diethylnitrosamine-induced mouse HCC (50 mg/kg) |
[138] |
Xanthohumol |
Inhibition of ER-Golgi translocation of SCAP/SREBPs by binding to Sec23/24 |
Normal liver |
None |
75 or 150 mg/kg dietary Xanthohumol inhibits SREBP-1 target gene expression in the liver in diet-induced obese mice |
[117] |
PF-429242 |
Inhibition of SREBP cleavage by inhibiting SIP |
Normal liver |
None |
PF-429242 with 10 or 30 mg/kg inhibits the expression of SREBP target genes in mice liver |
[126] |
HCC |
Huh-7 (90) |
None |
[144] |
GBM |
T98(15.0), U87- MG(15.2), A172 (27.6) |
None |
[128] |
Pancreatic |
MIA PaCa-2 (24.5) |
None |
[72] |
Nelfinavir |
Inhibition of SREBP cleavage by inhibiting S2P |
Liposarcoma |
LiSa-2 (−), SW872 (−) |
LiSa-2 (500 mg/kg) |
[132] |
Prostate |
DU145 (−), PC3 (−) |
None |
[134] |
1,10-phenanthroline |
Inhibition of SREBP cleavage by inhibiting S2P |
Prostate |
DU145 (−), PC3 (−) |
None |
[134] |
BF175 |
Inhibition of the transcription activity of SREBPs |
Normal liver |
None |
BF175, 0.2% per weight of diet for 8 weeks, decreases the expression of SREBP target genes in mouse liver and reduces hepatic and blood levels of lipids |
[137] |